Jos Kleinjans

Title: Jos Kleinjans: Innovator in Predicting Cardiotoxicity Risk

Introduction

Jos Kleinjans is a notable inventor based in Maastricht, Netherlands. He has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. His innovative approach utilizes a specific set of circulating microRNAs as biomarkers for this critical health concern.

Latest Patents

Kleinjans holds a patent for an invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention outlines an in vitro method for assessing the risk of cardiotoxicity by determining the expression levels of a combination of ten circulating miRNAs in biological samples from patients. The identified miRNAs include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. This invention not only serves as a predictive tool but also proposes a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs.

Career Highlights

Throughout his career, Jos Kleinjans has worked with esteemed institutions such as the Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana and Maastricht University. His work has been pivotal in advancing the understanding of cardiotoxicity in cancer treatment.

Collaborations

Kleinjans has collaborated with notable colleagues, including David Hervàs Marin and Ana Santaballa Beltràn. These partnerships have contributed to the development and validation of his innovative research.

Conclusion

Jos Kleinjans is a distinguished inventor whose work in predicting cardiotoxicity risk has the potential to significantly impact cancer treatment protocols. His innovative methods and collaborations highlight the importance of research in improving patient outcomes.